LUND, SWEDEN / ACCESS Newswire / February 21, 2025 / Cantargia (STO:CANTA) Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) full year report for 2024 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
"We now have two products in clinical development: CAN10 in immune and inflammatory diseases and nadunolimab in pancreatic cancer and other tumors. Both projects offer the possibility to transform the treatment and the lives of patients with debilitating and life-threatening illnesses. I aim to use all my experience to accelerate the creation of value from our programs and platform. We have a number of high-potential opportunities in front of us; prioritizing and capitalizing on these will be my principal focus in the next weeks and months " , said Damian Marron, Interim CEO of Cantargia.
Significant events in the fourth quarter
Cantargia reported new positive results regarding biomarkers and safety from the ongoing clinical phase 1 study with CAN10.
New results from the clinical studies CESTAFOUR and CAPAFOUR, where nadunolimab was tested in combination with chemotherapy in several cancers, were reported. Positive signals of effect were documented in non-small cell lung cancer and gastrointestinal cancers.
The clinical phase 1 study with CAN10 was expanded to explore higher dose levels of the antibody based on positive results.
Cantargia carried out a rights issue, which will generate proceeds of SEK 120 million, before deduction of issuing expenses.
Significant events after the end of the period
Göran Forsberg stepped down as Chief Executive Officer and Damian Marron was appointed interim CEO.
Financial information
January - December 2024
Net sales: SEK 0.0 M (0.0)
Operating loss: SEK -168.6 M (-290.0)
Loss after tax: SEK -161.7 M (-280.0)
Loss per share: before and after dilution: SEK -0.88 (-1.65)
Equity/assets ratio: 68 (75) per cent
Cash and cash equivalents: SEK 33.0 M (139.7)
Short-term investments: SEK 0.0 M (55.0)
Fourth quarter 2024
Net sales: SEK 0.0 M (0.0)
Operating loss: SEK -40.7 M (-71.1)
Loss after tax: SEK -39.4 M (-71.3)
Loss per share: before and after dilution, SEK -0.21 (-0.40)
In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on February 21, at 3:00 pm (CET), where Cantargia's Chairman, Magnus Persson, Interim CEO, Damian Marron, and CFO, Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.
If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast: https://cantargia.events.inderes.com/q4-report-2024
If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference: https://conference.inderes.com/teleconference/?id=5006304
The webcast will also be available on demand on Cantargia's corporate website: www.cantargia.com
For further information, please contact
Damian Marron, Interim CEO
Telephone: +46 (0)46-275 62 60
E-mail: damian.marron@cantargia.com
This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-21 07:00 CET.
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
Attachments
Cantargia Year End Report 2024
SOURCE: Cantargia
